Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancer

• DOI: 10.3389/fonc.2023.1219923
• Publication Date: 2023-08-04T12:20:55Z
• Authors: Guangxu Xu; Ziyi Zhao; Weiya Z. Wysham; Dario R. Roque; Ziwei Fang; Wenchuan Sun; Yajie Yin; Boer Deng; Xiaochang Shen; Chunxiao Zhou; Victoria Bae-Jump
• Keywords: Orlistat

Introduction Among all cancers, endometrial cancer is most strongly associated with obesity, more than 65% of cancers attributable to obesity and being overweight. Fatty acid synthase (FAS), a key lipogenic enzyme, expressed in tumors worse prognosis for this disease. Orlistat, an FAS inhibitor, FDA-approved weight loss medication that has demonstrated anti-tumor activity variety preclinical models. Methods In study, the Lkb1 fl/fl p53 mouse model endometroid was exposed three diet interventions, including high fat (obese), low (lean) switch from diet, then orlistat or placebo. Results The mice fed high-fat had significantly increased body tumor compared low-fat diet. Switching led reduction suppressed growth, as both groups. Orlistat effectively decreased obese inhibited growth obese, lean, groups through induction apoptosis. also showed anti-proliferative nine 11 primary cultures human cancer. Discussion Our findings provide strong evidence dietary intervention have vivo supports further investigation combination interventions prevention treatment